-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。マグナ・インターナショナル(MGA)は、第1四半期の調整後EPSが1.38ドルとなり、市場予想の0.78ドル(77%増)を大きく上回りました。これは、売上高と利益率が予想をはるかに上回ったことが要因です。売上高は3.1%増の103億8000万ドル(市場予想を1億1000万ドル上回る)、調整後EBITマージンは190ベーシスポイント上昇して5.4%(市場予想を120ベーシスポイント上回る)となりました。MGAは、2026年の売上高見通しを419億ドル~435億ドル(市場予想:424億ドル)から415億ドル~431億ドルに下方修正しました。その他の変更点は、純支払利息の予想を1億8000万ドルから1億6500万ドルに引き下げたことのみです。その他の従来のガイダンスは変更されていません。同社は通期EPSガイダンスを引き上げませんでしたが、予想を大きく上回ったことを考えると、今後は引き上げられる可能性が高いと考えています。ただし、現在のマクロ経済の不確実性を考慮すると、経営陣の慎重な姿勢は理解できます。MGAは自動車部品および機器分野において幅広い製品展開を行っており、北米最大の自動車部品サプライヤーとしての地位を確立していることから、第1四半期の好調な業績は他の自動車部品サプライヤーにもプラスの影響を与えると考えています。
Related Articles
Research Alert: CFRA Retains Hold View On Shares Of Incyte Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.
GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease
GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.Shares of GSK were down 1.2% in Friday trading.Price: $52.01, Change: $-0.30, Percent Change: -0.57%
ISM US Manufacturing Index Indicates Steady Expansion in April
The Institute for Supply Management's US manufacturing index was unchanged in April from the 52.7 reading in March, below the expectations for a 53.2 reading in a survey compiled by Bloomberg as of 7:40 am ET.There were gains in the readings for new orders and prices, but declines in production, employment and order backlogs.Other regional manufacturing sector readings have been generally positive, with exception of the Dallas and Chicago regions.The monthly national manufacturing reading from the Institute for Supply Management is reported as a headline index, with readings above 50 indicating expansion and those below 50 indicating contraction. Component indexes measure new orders, production, employment, and prices.An increase in the index further above 50 is considered a sign of a strong US manufacturing sector, generally a positive for manufacturing industry stocks. However, if that strength comes with rising input prices due to shortages, that could be a negative for stocks as well as bonds.